Recent studies to define characteristics of sarcomas which predict response or resistance to immunotherapy have included those examining tumor mutational burden, the tumor microenvironment (TME), and tumoral expression of immune checkpoint proteins PD-1, PD-L1, BTLA-4, CTLA4, and LAG3. Here, PDCD1 is linked to sarcoma.